@article{TCR15189,
author = {Steven G. Gray and Mark C. Wright and Stephen P. Finn},
title = {The “eyes” have it?—intra- and inter-observer reproducibility of the PD-L1 companion diagnostic assay},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 6},
year = {2017},
keywords = {},
abstract = {The role of the immune system in cancer is well established. Indeed, most potential cancer causing cells are detected and removed from our bodies by our immune system in a process called “immune surveillance”. However, at some point, tumors manage to evade our immune system often by expressing signals that inhibit the anti-tumor immune response (1). “The scientific turning point for cancer immunotherapy came with the understanding that T cell immune responses are controlled through on and off switches, so-called ‘immune checkpoints’ that protect the body from possibly damaging immune responses” (2). Blockade of these checkpoints has emerged as a new paradigm for the treatment of a cancer, including NSCLC (3).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/15189}
}